Our story
Seonix was founded by leading ophthalmologists and researchers who understand the impact of glaucoma vision loss on peoples’ lives. Building on many years of research, and access to some of the world’s largest glaucoma datasets, they identified thousands of genetic variants that increase an individual’s risk of glaucoma and developed this into a genetic risk score.
Seonix is now a growing company committed to bringing the benefits of improved genetic risk prediction information to eye health professionals, individuals, and researchers.
Our mission is to reduce blinding eye disease through the development of advanced techniques for clinical risk prediction.
Our story
Seonix was founded by leading ophthalmologists and researchers who understand the impact of glaucoma vision loss on peoples’ lives. Building on many years of research, and access to some of the world’s largest glaucoma datasets, they identified thousands of genetic variants that increase an individual’s risk of glaucoma and developed this into a genetic risk score.
Seonix is now a growing company committed to bringing the benefits of improved genetic risk prediction information to eye health professionals, individuals, and researchers.
Our mission is to reduce blinding eye disease through the development of advanced techniques for clinical risk prediction.
Chief Executive Officer
An experienced leader in the genomic diagnostics industry, Nick was a co-founder and CEO of BlueGnome, acquired by US sequencing giant Illumina in 2012.
Johnathon Matthews
LLB Bec BCom GAICD
Co-Founder
Extensive management experience in the medical devices industry. Mr Matthews also acts as a director of Austofix and BiomeBank.
Jamie Craig
MBBS DPhil FRANZCO
Co-Founder
Professor of Ophthalmology at Flinders University, Consultant Ophthalmologist and glaucoma sub-specialist, and leader of two of the world’s largest studies of glaucoma genetics.
Co-Founder
Professor of Statistical Genetics at the QIMR Berghofer Medical Research Institute, and international authority in glaucoma genetic risk prediction.
Alex Hewitt
MBBS PhD FRANZCO
Co-Founder
Professor of Ophthalmology at the University of Tasmania and the Centre for Eye Research Australia, and Board Member of the Ophthalmic Research Institute of Australia.
Co-Founder
Snow Fellow & Faculty Member at the Garvan Institute of Medical Research, with >15 years experience in academic genetic research and clinical medicine.
Chief Executive Officer
An experienced leader in the genomic diagnostics industry, Nick was a co-founder and CEO of BlueGnome, acquired by US sequencing giant Illumina in 2012.
Johnathon Matthews
LLB Bec BCom GAICD
Co-Founder
Extensive management experience in the medical devices industry. Mr Matthews also acts as a director of Austofix and BiomeBank.
Jamie Craig
MBBS DPhil FRANZCO
Co-Founder
Professor of Ophthalmology at Flinders University, Consultant Ophthalmologist and glaucoma sub-specialist, and leader of two of the world’s largest studies of glaucoma genetics.
Co-Founder
Professor of Statistical Genetics at the QIMR Berghofer Medical Research Institute, and international authority in glaucoma genetic risk prediction.
Alex Hewitt
MBBS PhD FRANZCO
Co-Founder
Professor of Ophthalmology at the University of Tasmania and the Centre for Eye Research Australia, and Board Member of the Ophthalmic Research Institute of Australia.
Co-Founder
Snow Fellow & Faculty Member at the Garvan Institute of Medical Research, with >15 years experience in academic genetic research and clinical medicine.
Chief Executive Officer
An experienced leader in the genomic diagnostics industry, Nick was a co-founder and CEO of BlueGnome, acquired by US sequencing giant Illumina in 2012.
Vice President – Global Sales
Optical Engineer with 40 Years’ experience in ophthalmology, vision science and sales operations. Howard has opened up and driven business into new markets for multinationals across Europe and the Asia Pacific.
Vice President -Business Development-Pharma
A seasoned executive with over 25 years of leadership in the life sciences and biopharmaceutical sectors, specializing in bioinformatics software, instrumentation, and clinical diagnostics. Tony has successfully guided four companies through strategic exits.
Vice President – Operations
Experienced in business development, analysis and strategy across the health and medical sector. Sinead has spent 20 years working for universities and startup companies, including as a director of two companies.
Chief Executive Officer
An experienced leader in the genomic diagnostics industry, Nick was a co-founder and CEO of BlueGnome, acquired by US sequencing giant Illumina in 2012.
Vice President – Global Sales
Optical Engineer with 40 Years’ experience in ophthalmology, vision science and sales operations. Howard has opened up and driven business into new markets for multinationals across Europe and the Asia Pacific.
Vice President -Business Development-Pharma
A seasoned executive with over 25 years of leadership in the life sciences and biopharmaceutical sectors, specializing in bioinformatics software, instrumentation, and clinical diagnostics. Tony has successfully guided four companies through strategic exits.
Vice President – Operations
Experienced in business development, analysis and strategy across the health and medical sector. Sinead has spent 20 years working for universities and startup companies, including as a director of two companies.
